Determining the Safety and Effectiveness of ENDOR Oral Combination Drug in the Treatment of Patients with Covid-19

Determining the Safety and Effectiveness of ENDOR Oral Combination Drug in the Treatment of Patients with Covid-19 Referred to Imam Khomeini Hospital in Tehran

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100601004076N26

Enrollment

200

Registered

2021-10-23

Start date

2021-11-22

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: In this study, the intervention group, in addition to the standard treatment according to national protocol, consumes two oral capsules of Endor every eight hours f

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Informed and voluntary oral and written consent of the patient or his / her guardian to participate in the study Age over 18 years SARS-CoV-2 virus PCR test positive or having one of the following conditions: Strong symptoms of COVID-19 disease, including fever, dry cough, and shortness of breath Existence of CT scan confirming lung involvement, especially ground glass view

Exclusion criteria

Exclusion criteria: Individuals whose Covid-19 test has not been approved Individuals who use drugs Individuals who drink alcohol Individuals who use immunosuppressive drugs Individuals under chemotherapy or radiotherapy Individuals who use growth hormone, testosterone and anabolic steroids

Design outcomes

Primary

Measure	Time frame
Complete Blood Count (CBC), Differentiation. Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Tests.;Erythrocyte sedimentation rate (ESR). Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Test.;C-Reactive Protein (CRP). Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Test.;Alanine Aminotransferease (ALT). Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Test.;Aspartate aminotransferase (AST). Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Test.;Creatinine. Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Tests.;Di-Dimer Test. Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Tests.;Respiratory Presentations. Timepoint: During Hospitalization. Method of measurement: Clinical Examination.;Weakness and lethargy. Timepoint: During Hospitalizations. Method of measurement: Clinical Examinations.;Fever. Timepoint: During Hospitalization. Method of measurement: Clinical Presentations.;Myalgia. Timepoint: During Hospitalization. Method of measurement: Clinical Examinations.;Dry Cough. Timepoint: During Hospitalization. Method of measurement: Clinical Examinations.;Existence of sputum. Timepoint: During Hospitalization. Method of measurement: Clinical Examinations.;Sore throat. Timepoint: During Hospitalization. Method of measurement: Clinical Examinations.;Diarrhea. Timepoint: During Hospitalization. Method of measurement: Clinical Examinations.;Shortness of breath. Timepoint: During Hospitalization. Method of measurement: Clinical Examination.;Rhinitis. Timepoint: During Hospitalization. Method of measurement: Clinical Examin	—

Measure

Time frame

Complete Blood Count (CBC), Differentiation. Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Tests.;Erythrocyte sedimentation rate (ESR). Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Test.;C-Reactive Protein (CRP). Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Test.;Alanine Aminotransferease (ALT). Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Test.;Aspartate aminotransferase (AST). Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Test.;Creatinine. Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Tests.;Di-Dimer Test. Timepoint: During Three days of Hospitalization and at the time of discharging. Method of measurement: Laboratory Tests.;Respiratory Presentations. Timepoint: During Hospitalization. Method of measurement: Clinical Examination.;Weakness and lethargy. Timepoint: During Hospitalizations. Method of measurement: Clinical Examinations.;Fever. Timepoint: During Hospitalization. Method of measurement: Clinical Presentations.;Myalgia. Timepoint: During Hospitalization. Method of measurement: Clinical Examinations.;Dry Cough. Timepoint: During Hospitalization. Method of measurement: Clinical Examinations.;Existence of sputum. Timepoint: During Hospitalization. Method of measurement: Clinical Examinations.;Sore throat. Timepoint: During Hospitalization. Method of measurement: Clinical Examinations.;Diarrhea. Timepoint: During Hospitalization. Method of measurement: Clinical Examinations.;Shortness of breath. Timepoint: During Hospitalization. Method of measurement: Clinical Examination.;Rhinitis. Timepoint: During Hospitalization. Method of measurement: Clinical Examin

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedAhmad SeyedAlinaghi

Tehran University of Medical Sciences

s_a_alinaghi@yahoo.com+98 21 6658 1583

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026